Mounjaro vs Farxiga
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Mounjaro | US Farxiga | |
|---|---|---|
| Generic name | tirzepatide | dapagliflozin |
| Drug class | GIP/GLP-1 Receptor Agonist | SGLT2 Inhibitor |
| Treats | Type 2 diabetes | Type 2 diabetes, heart failure, chronic kidney disease |
| Category | Diabetes | Diabetes |
| Manufacturer | Eli Lilly | AstraZeneca |
| Year approved | 2022 | 2014 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $350M | $220M |
| Common side effects | Nausea, Diarrhea, Decreased appetite, Vomiting | Genital yeast infections, Urinary tract infections, Dehydration, Low blood pressure |
Frequently asked questions
Is Mounjaro or Farxiga better?
Neither is universally "better." Mounjaro (tirzepatide) and Farxiga (dapagliflozin) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Mounjaro and Farxiga?
Mounjaro is a GIP/GLP-1 Receptor Agonist made by Eli Lilly, while Farxiga is a SGLT2 Inhibitor made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Mounjaro has the larger estimated TV advertising budget of the two.